White Blood Cell Growth Factors

Publication Date: July 21, 2015

Key Points

Key Points

Prophylactic use of colony-stimulating factors (CSFs) to reduce the risk of febrile neutropenia is warranted when the risk of febrile neutropenia is approximately 20% or higher and no other equally effective and safe regimen that does not require CSFs is available.

Primary prophylaxis is recommended for the prevention of febrile neutropenia in patients who are at high risk on the basis of age, medical history, disease characteristics, and myelotoxicity of the chemotherapy regimen.

Dose-dense regimens that require CSFs should be used only within an appropriately designed clinical trial or if supported by convincing efficacy data.

Current recommendations for the management of patients exposed to lethal doses of total-body radiotherapy, but not doses high enough to lead to certain death as a result of injury to other organs, include the prompt administration of CSFs.

Diagnosis

...gnosis...

Table 1. Patient Risk Factors for Febrile Neutrop...


Table 2. Patient Risk Factors for...


Treatment for Adult Patients

...reatment for Adult Patie...

...axis with a CSF starting with the fir...


...y prophylaxis with a CSF is recommended for...


...s should not be routinely used for...


...be routinely used as adjunctive treat...


...cancer and lymphoma] ( EB , H , B , S )3336...

...urothelial cancer] ( EB , H , H , M...


...ed alone, after chemotherapy, or in combi...


...administered after autologous stem-cel...


...e administered after allogeneic stem-cell transpla...


...ctic CSFs for patients with diffuse aggressive...


...stim, filgrastim, tbo-filgrastim, and filgr...


...commendations for the management o...


Treatment for Pediatric Patients

...ment for Pediatric Pati...

...s in pediatric patients will almost always...


...pediatric indications in which dose-inte...


...should not be used in pediatric pati...


Table 3. Dosing and Administration of CSFs

.... Dosing and Administration of CSFsHaving trouble...